Shrinking a tumor before surgery helped protect a young patient’s voice. MSK experts took an unconventional approach, using larotrectinib to make a less extensive operation possible. Read about her treatment:

Catch up on the cancer research MSK presented at #ESMO26#. 🔬 Our roundup covers a pancreatic cancer vaccine, targeted therapy for advanced GIST, and new treatment approaches for ovarian cancer, lung cancer, and sarcoma. Learn more:

Congratulations to the recipients of this year's MRF Breakthrough Consortium (MRFBC) Pilot Translational Awards: Shankar Suman, PhD of the @MayoClinic in Rochester and Michael Postow, MD of @MSKCancerCenter! The MRFBC is a national network of 34 centers of excellence in melanoma that collaborate to accelerate research and the development of the most promising therapies in melanoma treatment. Learn more about this year's MRFBC Pilot Translational Awardees:

This October, Breast Cancer Awareness Month, we spotlight Breast Radiation Oncologist Dr. J. Isabelle Choi. "It is a privilege to walk alongside my patients through treatment and help them get back to the things that matter most to them." #BreastCancerAwarenessMonth# #RadOnc#

As members of the @CAIAorg, MSK is helping accelerate development and deployment of AI models to improve cancer care "Rather than developing separate tools for every clinical question, we are training foundational models across institutions," says Dr. @SohrabShah, Chief of Computational Oncology in the Department of Epidemiology and Biostatistics at MSK. "Our goal is to develop models that learn from patients full clinical trajectories with multimodal data and at national scales. This will ultimately inform clinical recommendations for new patients, leading to improved personalized treatment and care." Learn more ⬇️

Join us next week, November 5–6, for the 10th Advances in Colorectal Oncology Symposium @MSKCancerCenter, a milestone event bringing together international experts to explore the latest advances, emerging strategies, and real-world challenges in multidisciplinary colorectal cancer care. Hear from @DrPaulRomesser as he shares what makes this year’s program especially exciting and why you won’t want to miss it. We hope you’ll join us! Learn more and register: @jgarciaaguilar

There's a lot of buzz around mRNA #cancervaccines#, but how do they actually work? These vaccines help train your body’s immune system to recognize the unique genetic signature of cancer cells. Once activated, the immune system can: 🔹 Target and attack cancer cells while helping spare healthy cells 🔹 Work alongside other cancer treatments 🔹 Create a lasting immune response that may help prevent cancer from returning or spreading 📽️ Hear more from Dr. Vinod Balachandran (@TheVinodLab), Director of the Olayan Center for Cancer Vaccines at MSK, about what patients should know about experimental mRNA cancer vaccines.

MSK Employee Spotlight | @dana_peer, Chair of the Computational and Systems Biology Program the Sloan Kettering institute (SKI) at Memorial Sloan Kettering Cancer Center (MSK), was recently elected to the National Academy of Medicine (NAM), one of the most respected distinctions in science and medicine. Dr. Pe’er is a preeminent computational biologist whose work has transformed how scientists use large-scale genomic data to understand complex biological systems. Her lab has pioneered widely used machine-learning and AI approaches to reveal how cells take on certain states, communicate with one another, and organize into tissues. She applies these approaches to fundamental questions in organismal development and in cancer, with a focus on cellular plasticity, metastasis, and how cancer cells shape — and are shaped by — their tissue ecosystems during progression and therapy. Currently, Dr. Pe’er is the Chair of Computational and Systems Biology and Scientific Director of SKI’s Single-cell Analytics Innovation Lab, as well as a Howard Hughes Medical Institute Investigator. She holds the Alan and Sandra Gerry Endowed Chair. Join us in congratulating Dr. Pe'er in the comments below!

MSK Employee Spotlight | Dr. Ross Levine, Chief Scientific Officer (CSO) at MSK, was recently elected to the @theNAMedicine (NAM), one of the most respected distinctions in science and medicine. Dr. Levine’s research focuses on the genetic changes that drive myeloid malignancies, including myeloproliferative neoplasms and acute myeloid leukemia, and translating these discoveries into more effective treatments. As MSK’s CSO, he leads basic and translational research strategy, overseeing programs, centers, technology cores, and the financial and operational resources that support MSK’s research enterprise. Previously, Dr. Levine served as HOPP's first chief of the Molecular Cancer Medicine Service, inaugural Director of the Center for Hematologic Malignancies, and Senior Vice President for Translational Research at Memorial Hospital. He holds the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes. Join us in congratulating Dr. Levine in the comments below!

🚨 MSK’s @AndreaCercek presented full interim results from the AZUR-1 trial at #ESMO26# in Madrid. The trial tested Jemperli (dostarlimab) in people with stage 2 and 3 rectal cancer whose tumors are mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H). Among patients for whom the approach worked, no cancer has returned during follow-up. The approach, developed at MSK by Dr. Cercek and Dr. Luis Diaz Jr. (@ldiaz1971), allows some patients to avoid treatments that can have life-altering consequences, including infertility and bowel and bladder dysfunction. The @FDA approved the approach in October 2026, calling it "groundbreaking. “It’s incredibly rewarding,” says Dr. Cercek, “to get these happy tears and happy emails from the patients who finish treatment and realize, ‘Oh my God, I get to keep all my normal body functions that I feared I might lose to radiation or surgery.’” Learn more:

#PingChi# from @MSKCancerCenter presented on the #final# results of FIH #NB003# trial, a potent and selective KIT inhibitor in GISTs. Broad spectrum of activity seen in different mutations. Phase 3 trial compared with #regorafenib# planned. @ctosociety @Liferaftgroup @myESMO #ESMO26# #ESMOAmbassadors#

Tomorrow at #ESMO26#: MSK hepatopancreatobiliary surgeon Dr. Vinod Balachandran (@TheVinodLab) will discuss immunotherapy in pancreatic cancer and overcoming barriers to success. 🗓️ Monday, October 26 | 11:15 a.m. CET

Tomorrow at #ESMO26#: MSK sarcoma medical oncologist Dr. Lauren Banks will present research on lifileucel in undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. 🗓️ Monday, October 26 | 9:34 a.m. CET

Grateful to present 3 posters at #ESMO2026# in Madrid! 🇪🇸 1. Pathogenic germline ATM alterations define a distinct pancreatic cancer subtype with improved survival, less liver metastases and reduced KRAS signaling. @CentralParkWMD @EileenMOReilly @ciacobu @CpcrMsk 2. POSTN+ fibroblasts identify an aggressive tumor microenvironment and poorer survival in pancreatic cancer (#PRODIGE24#). @RemyNicolle @cros_jerome 3. Early CT-derived body composition changes predict survival in biliary tract cancer patients receiving immunotherapy, independently of radiological progression, CA19-9, ECOG PS, and weight loss (#PRODIGE57#). @DelayeMatthieu Grateful to all collaborators at @MSKCancerCenter, @institut_curie, and GERCOR/PRODIGE! #PancreaticCancer# #GIOncology#

Today at #ESMO26#: Research co-authored by MSK gastrointestinal medical oncologist Dr. Yelena Janjigian will be presented from CLARITY-Gastric 01, a phase 3 study of sonesitatug vedotin in second- or later-line advanced or metastatic Claudin 18.2-positive gastroesophageal carcinoma. 🗓️ Sunday, October 25 | 5:18 p.m. CET

AZUR-1 presented by @AndreaCercek @MSKCancerCenter: dostarlimab x 6 months in locally advanced dMMR/MSI-H #rectalcancer# (recently FDA approved): 71% clinical complete response (cCR) rate, 100% durable (2 cCR patients had surgery with path complete response (pCR)), overall 76% had cCR at 12 months or pCR #ESMO26# @myESMO #crcsm#

Coming up at #ESMO26#: MSK thoracic surgeon Dr. Daniela Molena will discuss perioperative therapy for locally advanced gastric and gastroesophageal cancer. 🗓️ Sunday, October 25 | 4:30 p.m. CET

At #ESMO26#, @DrDarrenFeldman (@MSKCancerCenter) discusses phase 1 data showing ixotatug vedotin drives notable responses in heavily pretreated #GermCellTumors#, with manageable ADC safety and potential phase 2 plans. 🎥 WATCH: #Oncology# #CancerTreatment#

Tomorrow at #ESMO26#: MSK gastrointestinal medical oncologist @AndreaCercek will present the first results from the global AZUR1 trial of dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer. 🗓️ Sunday, October 25 | 11:00 a.m. CET

Memorial Sloan Kettering Cancer Center (MSK) and @OpenEvidence have partnered to bring cutting-edge AI and precision oncology expertise closer to the point of care. By integrating OpenEvidence into MSK's Epic workflow and embedding MSK's @OncoKB™ precision oncology knowledge base directly into OpenEvidence, clinicians can access trusted, evidence-based insights within their existing clinical workflows. “We're excited that OpenEvidence will widen OncoKB's reach, bringing MSK's expert interpretation of a patient's unique cancer genetics to cancer care providers across the U.S. to help them make molecularly informed treatment decisions,” says Dr. Debyani Chakravarty (@CDebyaniPhD), a lead scientist for OncoKB at MSK. Learn more about this new collaboration: